Elevated Levels of Circulating lncRNAs LIPCAR and MALAT1 Predict an Unfavorable Outcome in Acute Coronary Syndrome Patients

Coronary artery disease (CAD) is a leading cause of mortality worldwide. In this study, we aimed to assess the potential of plasma long non-coding RNAs (lncRNAs) LIPCAR and MALAT1 and microRNAs (miRNAs) miR-142-3p and miR-155-5p to discriminate unstable CAD patients from stable ones. 23 stable angin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-08, Vol.24 (15), p.12076
Main Authors: Barbalata, Teodora, Niculescu, Loredan S, Stancu, Camelia S, Pinet, Florence, Sima, Anca V
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Angina pectoris
Apolipoproteins
Biomarkers
Cardiac patients
Cardiology
Cardiology and cardiovascular system
Comparative analysis
coronary syndrome
Heart attack
Heart attacks
Heart failure
Human health and pathology
Hyperglycemia
Life Sciences
LIPCAR
long non-coding RNA
MALAT1
MicroRNA
MicroRNAs
miR-142
miR-155
Mortality
Patient outcomes
Plasma
Prognosis
Proteins
Taiwan
Unstable angina
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronary artery disease (CAD) is a leading cause of mortality worldwide. In this study, we aimed to assess the potential of plasma long non-coding RNAs (lncRNAs) LIPCAR and MALAT1 and microRNAs (miRNAs) miR-142-3p and miR-155-5p to discriminate unstable CAD patients from stable ones. 23 stable angina (SA), 21 unstable angina (UA), and 50 ST-segment elevation myocardial infarction (STEMI) patients were enrolled; their plasma was collected. ncRNA plasma levels were evaluated using RT-qPCR. All measured ncRNA levels were significantly increased in UA patients' plasma compared to SA patients' plasma and in STEMI-with major adverse cardiovascular event (MACE) patients' plasma vs. STEMI-without MACE patients' plasma. ROC analysis showed that increased levels of LIPCAR and MALAT1 were associated with UA, and the prognostic model improved with the addition of miR-155-5p levels. The assessed lncRNAs discriminated between hyperglycemic (HG) and normoglycemic (NG) UA patients, and they were associated with MACE incidence in STEMI patients; this prediction was improved by the addition of miR-142-3p levels to the ROC multivariate model. We propose LIPCAR and MALAT1 as effective diagnostic markers for vulnerable CAD, their association with HG in UA patients, and as robust predictors for unfavorable evolution of STEMI patients.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241512076